Tear Osmolarity

Your tears contain water together with dissolved substances such as salts, proteins and other molecules. Osmolarity describes how concentrated those dissolved particles are in the tear fluid.

A simple way to imagine it is: if water is lost while dissolved substances remain, the remaining fluid becomes more concentrated.

In dry eye, disturbances in tear production, tear-film stability, evaporation and other processes can contribute to this increased concentration. When tear osmolarity becomes abnormally high, this is called tear hyperosmolarity.

Hyperosmolarity is not simply a number on a diagnostic machine. It is involved in dry-eye pathophysiology.

An excessively concentrated tear environment can place stress on ocular-surface cells and contribute to inflammatory signalling and surface damage. At the same time, tear-film instability and other dry-eye mechanisms can contribute to increasing osmolarity. This can become part of a self-perpetuating cycle:

tear-film disturbance→increased concentration→ocular-surface stress→further loss of homeostasis

For this reason, TFOS DEWS III includes hyperosmolarity as one of the important etiological factors in dry eye disease.

In clinical practice, a small sample of tears is usually collected from the tear meniscus along the lower eyelid. A point-of-care device then analyzes the sample and provides an osmolarity value. The procedure requires only a tiny amount of tear fluid and can be performed quickly.

But there is an important limitation: the instrument is sampling tears from the tear meniscus. It is not continuously measuring osmolarity across the entire surface of the eye.

Probably not. This is an important part of understanding the test.

During tear-film breakup and evaporation, very high local concentrations may temporarily develop in small areas of the ocular surface. Experimental modelling suggests that local osmolarity at sites of tear-film destabilization may become dramatically higher than the value measured from the tear meniscus.

But current point-of-care clinical devices cannot directly sample those tiny unstable areas. They sample the tear reservoir at the eyelid margin.

So the number on your report is tear-meniscus osmolarity at the time and location of sampling. It is not a map of osmolarity across the entire ocular surface.

TFOS DEWS III currently uses, for the TearLab system: 308 mOsm/L or higher in either eye, or a difference greater than 8 mOsm/L between the two eyes, as a positive osmolarity finding indicating loss of tear-film and ocular-surface homeostasis.

But there is an important detail: these thresholds were established for the TearLab device. They should not automatically be transferred to every osmolarity instrument.

And even with TearLab, the result should not be treated as a biological cliff. An eye measuring 307 and an eye measuring 309 are not necessarily fundamentally different biological states. The threshold is a clinical decision point used to help interpret a continuous biological measurement.

Yes. This is one of the places where osmolarity differs from many of the tests we have discussed.

In the TFOS DEWS III diagnostic framework, tear osmolarity is one of the three principal objective markers of loss of homeostasis, alongside tear-film instability and ocular-surface staining.

In a patient with compatible symptoms, a positive homeostasis marker can contribute directly to establishing the diagnosis of dry eye disease after appropriate differential diagnosis. So osmolarity is not merely a test for finding a possible subtype or cause. It can be part of the actual diagnostic process.

No. This is extremely important.

Dry eye is heterogeneous. A patient may demonstrate loss of homeostasis through tear-film instability or ocular-surface staining while osmolarity measured at that particular examination remains below the diagnostic threshold.

TFOS DEWS III specifically warns against relying on only one homeostasis test when trying to exclude dry eye. Studies evaluating the diagnostic algorithm found that using only one of the three major homeostasis markers could miss a meaningful proportion of patients who otherwise met diagnostic criteria.

So normal osmolarity does not mean no dry eye.

Not by itself. A test result always needs clinical context. Symptoms, differential diagnosis and other ocular-surface findings still matter. And osmolarity measurements themselves have limitations. A high result is evidence that tear-film homeostasis may be disturbed. It should not be interpreted in isolation as a complete explanation of what is happening to the eye.

No. A high osmolarity result tells us something about tear-film homeostasis. It does not tell us why that homeostasis was lost. For example, hyperosmolarity may occur in a dry-eye picture involving aqueous deficiency, tear-film instability, lipid-related abnormalities, exposure, or multiple interacting mechanisms.

So a high number does not mean “I have aqueous-deficient dry eye.” And it does not mean “I have evaporative dry eye.” Those questions require additional testing.

Not reliably. It may sound logical that 310 = mild, 320 = moderate, 330 = severe. But dry eye does not work that neatly.

TFOS DEWS III notes that tear-meniscus osmolarity explains very little of the variation seen in other tear-film and ocular-surface homeostasis signs. It is therefore unreliable as a standalone way of determining dry-eye severity. A person with a higher osmolarity measurement does not automatically have worse symptoms, more staining or more severe gland dysfunction than someone with a lower measurement.

So osmolarity is a marker of disturbed homeostasis — not a simple dry-eye severity meter.

Yes. This is one of the major limitations of the test. Tear osmolarity is dynamic. And studies of point-of-care osmolarity devices have reported considerable variability between repeated measurements. A single measurement may therefore not perfectly represent a person’s usual tear-film state. TFOS DEWS III specifically acknowledges concerns that current instrumentation may not produce sufficiently repeatable results from a single in-vivo measurement.

Enough that it deserves attention.

A systematic review examining TearLab measurements in 1,362 eyes of healthy, asymptomatic participants without clinical signs of dry eye found substantial measurement variability. Remarkably, 28.3% of those healthy eyes produced values above 308 mOsm/L, the commonly used TearLab diagnostic threshold.

That does not mean the threshold is meaningless. But it does demonstrate why one isolated measurement should not automatically become a diagnosis. Another study that repeatedly measured the same eyes found occasional outlying values to be common and concluded that multiple measurements were needed to obtain a more reliable estimate.

This is exactly the kind of limitation patients should understand when they are handed a very precise-looking number.

Yes. Different point-of-care osmolarity systems use different technologies and do not necessarily produce interchangeable measurements. A study comparing two clinical osmolarity instruments found that they agreed on dry-eye classification in only 46.5% of cases. Both also showed poor repeatability in vivo when only single measurements were considered.

So if one clinic obtains one value and another clinic using a different instrument obtains another, the difference should not automatically be interpreted as a biological change in your eyes. The device and measurement conditions matter.

Historically, variability between the two eyes has attracted particular interest. The TearLab-based TFOS criterion includes an inter-eye difference greater than 8 mOsm/L as a positive finding. The idea is that unstable tear-film homeostasis may produce greater variability between eyes.

But the evidence here is not completely straightforward. TFOS DEWS III notes that one study supported the validity of inter-eye difference alone, while another did not. A separate study of 191 participants found that an inter-eye difference greater than 8 mOsm/L, when neither eye itself had high osmolarity, was poorly associated with symptoms and other dry-eye signs.

So inter-eye difference can contribute information, but it should not be interpreted as an infallible standalone rule.

Yes. Tear osmolarity is not necessarily a fixed personal number. It can vary.

Interestingly, some research suggests that variability over time may itself contain useful information about tear-film homeostasis. TFOS DEWS III notes that daily variation has been proposed as a potentially better marker of dry eye than a single measurement.

The problem is practical: repeated measurements throughout the day are difficult to incorporate into routine clinical care. So most patients receive only a snapshot.

Imagine your osmolarity result is 315 mOsm/L. The machine has genuinely measured something. But that number does not automatically mean “My eyes are always at 315.”

It means: “This tear sample, taken from this location, at this moment, with this device, produced a value of 315.”

That finding can be clinically useful. But it becomes much more meaningful when interpreted alongside other information.

That can happen. You might have a short NIBUT but normal osmolarity, significant staining but normal osmolarity, or high osmolarity with relatively mild findings elsewhere. That does not automatically mean that one test is wrong. Different tests measure different aspects of the dry-eye system.

NIBUT asks how stable the tear film is. Staining asks what is happening to the ocular surface. Osmolarity asks how concentrated the sampled tear fluid is. These findings are related through tear-film homeostasis. But they are not measuring the same thing.

Because the underlying biology matters. Hyperosmolarity is an important part of dry-eye pathophysiology. And osmolarity can provide information that is not identical to tear-film stability or ocular-surface staining.

TFOS DEWS III therefore continues to include it as one of the key homeostasis markers. At the same time, the report openly acknowledges limitations in repeatability, device differences and correlation with other dry-eye signs.

Those two ideas are not contradictory. A biologically important marker can still be difficult to measure perfectly in clinical practice.

It can provide evidence about:

• •the concentration of the sampled tear fluid
• •whether tear-film homeostasis may be disturbed
• •one aspect of the ocular-surface environment at the time of testing

Together with symptoms and other homeostasis tests, it can contribute to the diagnosis of dry eye disease.

By itself, it cannot tell you:

• •why your tear film is abnormal
• •whether you have aqueous-deficient or evaporative dry eye
• •how severe your symptoms should be
• •how damaged your ocular surface is
• •how your meibomian glands are functioning
• •what your osmolarity is at every point across your ocular surface throughout the day

And one isolated number should not automatically be treated as your permanent “dry-eye score.”